Meet the Minds: Dr. Stephen Matthews explores how our earliest experiences can shape lifelong health
What if the foundations of our health are laid before we are even born?
That question has driven Dr. Stephen Matthews’ research for more than three decades. A Senior Investigator at Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI), Dr. Matthews studies how the environment during pregnancy can influence fetal development and potentially affect the health of the child years or even decades later.
His work spans neuroscience, pregnancy, epigenetics and population health, with a goal of understanding not only how early experiences leave their mark, but how that knowledge could help prevent health problems before they begin.
Dr. Matthews also co-directs the Ontario Birth Study (OBS), a research platform embedded at Mount Sinai Hospital that follows families from early pregnancy through childhood. By combining detailed health information with biological samples collected over time, OBS is helping researchers connect the dots between our earliest environments and future health.
Q: What first drew you to studying how our earliest experiences can shape health throughout life?
Dr. Matthews: I trained in molecular neuroscience, studying how the brain controls our stress response. When I moved to Canada, I joined a very strong perinatal research group and began thinking about how those same systems develop before birth.
Around this time, in the early ’90s, landmark research was showing links between low birth weight — a sign the baby may have faced challenges in the womb — and increased risks of cardiovascular disease, Type 2 diabetes and other health problems later in life.
That really piqued my interest: How can an experience as a fetus be linked to health decades later? We now have an entire field called the developmental origins of health and disease, or DOHaD, devoted to that question. We know the phenomenon is real. The challenge now is understanding the mechanisms and, importantly, asking how we can use what we already know to transform people’s lives.
Q: How can something that happens during pregnancy have effects that last so long?
Dr. Matthews: The fetal period is an incredibly important time for development, particularly for the brain. About 99 per cent of the neurons functioning in our brains as adults were already there at birth. That means exposures during fetal life can have significant effects on how the brain develops, how it functions throughout life and potentially how it ages.
One area we’ve studied extensively is exposure to glucocorticoids, or stress hormones. During a healthy pregnancy, a natural surge of the stress hormone cortisol late in gestation helps prepare organs such as the lungs, kidneys and brain for life outside the uterus.
But timing matters. If the developing fetus is exposed to high levels of these hormones earlier, either through stress or medications, they can affect the developing brain differently.
We’ve found that these early exposures can leave a kind of biological memory. Exposure to glucocorticoids too early can influence the epigenome — chemical “tags” associated with our DNA that affect how genes are read and used by cells. The genetic code itself doesn’t change, but the way the body reads that code can. Our research suggests these changes can persist later in life, potentially affecting brain function and how an individual responds to stress.
Q: How could understanding these early effects ultimately improve care?
Dr. Matthews: A good example is glucocorticoid treatment for pregnant people at risk of preterm birth. These medications are extremely important because they rapidly mature the fetal lungs and have saved many babies’ lives.
But years ago, repeated courses were sometimes given because it can be difficult to predict exactly when a preterm birth will occur. Our research began showing that while these medications benefit the fetus’s lungs, repeated exposure could have unintended effects on other developing organs, including the brain.
That research contributed to a shift in how clinicians think about repeated courses of glucocorticoids. The question isn’t whether we should use these life-saving medications; it’s how we can use them as effectively and precisely as possible.
We’re now studying protective systems in the developing brain, including the blood-brain barrier. Ultimately, if we understand how those systems work, we may be able to find ways to better protect the brains of babies born prematurely during a particularly vulnerable period of development.
Q: What makes the Ontario Birth Study such a powerful resource for answering these questions?
Dr. Matthews: The OBS allows us to begin collecting information at about 11 to 13 weeks of pregnancy and then follow children through their early years. We collect detailed information about pregnancy, exposures and environments, along with biological samples, and then look at pregnancy outcomes and children’s health and neurodevelopment.
This gives us a carefully characterized group of families whom we can follow longitudinally. Rather than looking at someone after a health problem develops and trying to reconstruct what happened years earlier, we already have information and samples from pregnancy.
For example, researchers are using the OBS to investigate whether inflammatory markers in the mother during pregnancy are associated with neurodevelopmental outcomes in children. Because the OBS isn’t designed to answer just one research question, the information and samples we've collected can continue to help us explore new questions as the science evolves.
This has already led to important research looking at its impact on pregnant people and their children.
Q: Why is it important that the OBS is embedded within the health-care system?
Dr. Matthews: One of the unique things about the OBS is that we have been continuously recruiting. Participants are already coming to Mount Sinai Hospital for their pregnancy care, and we’re able to integrate the research into our health system.
We saw the value of that during COVID-19. When many human research studies had to stop, the OBS was able to continue because participants still needed to come to the hospital for their regular care. That meant we could collect information and biological samples throughout the pandemic and subsequently study its effects.
That ability to respond to questions we could never have anticipated when the OBS began is incredibly valuable. Today, for example, we’re studying associations between inflammatory markers during pregnancy and neurodevelopmental outcomes in children. As science evolves, the questions we can ask of this cohort continue to evolve, too.
Q: Where do you see the greatest opportunity to change lifelong health?
Dr. Matthews: The evidence increasingly tells us that the earlier we can intervene, the greater the potential impact, which may mean even before pregnancy.
We now know that the health of both women and men around conception can influence the earliest stages of development. That’s important because this shouldn’t be about placing responsibility or blame on mothers. We need to think much more broadly about how we support the health of young people and families.
That thinking is behind the Healthy Life Trajectories Initiative, or HeLTI, an international program in which Sinai Health researchers have played a major role. Rather than simply identifying associations between early exposures and later outcomes, we’re testing interventions, beginning before conception, that support mental health, nutrition, physical health and healthier environments.
For me, that’s an exciting evolution of this field. We don’t have to understand every molecular mechanism before we start using the evidence we have to help improve health.
Q: What will it take to realize the full potential of this research?
Dr. Matthews: Long-term research depends on people: the researchers and trainees who bring new ideas, expertise and technologies to these questions, as well as the infrastructure that allows us to continue building resources such as the OBS.
Philanthropy can play an incredibly important role in supporting that next generation. I’ve seen how donor-funded fellowship programs create opportunities for talented postdoctoral researchers to enter human developmental health and work across institutions and disciplines.
Here at Sinai Health, we have an extraordinary concentration of researchers working in human development. Through the Alliance for Human Development, we’re bringing together work such as the OBS, HeLTI and fundamental research to understand how early environments influence long-term outcomes.
The opportunity is to keep building that community and those resources so we can follow the science, wherever it takes us. If we can better understand the earliest origins of health, identify where and when we can intervene, we can improve health not just during pregnancy or childhood, but across an entire lifetime.
How you can help
Dr. Stephen Matthews is working to understand how our earliest environments shape health across a lifetime, and how that knowledge can help prevent challenges before they begin. By uncovering the connections between pregnancy, fetal development and later health, his research could help identify opportunities to intervene earlier and give children and families the healthiest possible start.
Want to support transformational research like this? Donate today. Please select Research – Lunenfeld-Tanenbaum Research Institute from the gift designation dropdown menu, or contact:
Jess Duggan, Senior Philanthropy Director
[email protected]